Feng Hongxiang, Liang Chaoyang, Shi Yuhui, Liu Deruo, Zhang Jin, Zhang Zhenrong
Department of Thoracic Surgery, China-Japan Friendship Hospital, Beijing 100029, China.
J Clin Med. 2022 Oct 19;11(20):6154. doi: 10.3390/jcm11206154.
Lung cancer is the major cause of cancer-related deaths around the world. Lung adenocarcinoma (LUAD), the most common subtype of lung cancer, contributed to the majority of mortalities and showed different clinical outcomes in prognosis. Tumor-infiltrated immune cells at the tumor site are associated with better survival and immunotherapy response. Thus, it is essential to further investigate the molecular mechanisms and new prognostic biomarkers of lung adenocarcinoma development and progression. In this study, a six-gene signature (CR2, FGF5, INSL4, RAET1L, AGER, and TNFRSF13C) was established to predict the prognosis of LUAD patients, as well as predictive value. The prognostic risk model was also significantly associated with the infiltration of immune cells in LUAD microenvironments. To sum up, a novel immune-related six-gene signature (CR2, FGF5, INSL4, RAET1L, AGER, and TNFRSF13C) was identified that could predict LUAD survival and is highly related to B cells and dendritic cells, which may provide a theoretical basis of personalized treatment for targeted immunotherapy.
肺癌是全球癌症相关死亡的主要原因。肺腺癌（LUAD）是肺癌最常见的亚型，导致了大多数死亡病例，并且在预后方面表现出不同的临床结果。肿瘤部位的肿瘤浸润免疫细胞与更好的生存率和免疫治疗反应相关。因此，进一步研究肺腺癌发生发展的分子机制和新的预后生物标志物至关重要。在本研究中，建立了一个六基因特征（CR2、FGF5、INSL4、RAET1L、AGER和TNFRSF13C）来预测LUAD患者的预后以及预测价值。该预后风险模型也与LUAD微环境中免疫细胞的浸润显著相关。综上所述，鉴定出一种新的免疫相关六基因特征（CR2、FGF5、INSL4、RAET1L、AGER和TNFRSF13C），其可以预测LUAD的生存情况，并且与B细胞和树突状细胞高度相关，这可能为靶向免疫治疗的个性化治疗提供理论依据。
